Novo Integrated Sciences, Inc. Common Stock
NVOS
NVOS was delisted on the 5th of November, 2024.
8 hedge funds and large institutions have $792K invested in Novo Integrated Sciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
18% less capital invested
Capital invested by funds: $965K → $792K (-$173K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$42.8K |
| 2 |
BlackRock
New York
|
+$8.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.61K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$52K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $479K | – | – | – |
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $162K | – | – | – |
|
|
3
BlackRock
New York
| $52K | +$8.9K | +436 | +18% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $51K | +$4.49K | +220 | +9% |
|
|
5
State Street
Boston,
Massachusetts
| $39K | +$42.8K | +2,099 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $7K | -$1K | -49 | -12% |
|
|
7
UBS Group
Zurich,
Switzerland
| $2K | +$2.61K | +128 | New |
|
|
CH
8
CVI Holdings
Wilmington,
Delaware
| – | -$52K | -2,249 | Closed |
|
|
9
Wells Fargo
San Francisco,
California
| – | +$20 | +1 | +17% |
|
NVOS Hedge Fund Activity: Q2 2022 in Review
8 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Novo Integrated Sciences, Inc. Common Stock (NVOS) for Q2 2022, worth a combined $792K — down 18% from $965K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NVOS positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $42.8K. The largest seller was CVI Holdings, exiting entirely with an estimated $52K sold.
- 8 institutional investors held Novo Integrated Sciences, Inc. Common Stock (NVOS) as of Q2 2022, up from 7 in Q1 2022.
- Funds reported $792K of Novo Integrated Sciences, Inc. Common Stock stock for Q2 2022, down 18% quarter-over-quarter.
- 2 funds opened new Novo Integrated Sciences, Inc. Common Stock positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Novo Integrated Sciences, Inc. Common Stock buyer in Q2 2022 was State Street, an estimated $42.8K added.
- The largest Novo Integrated Sciences, Inc. Common Stock seller in Q2 2022 was CVI Holdings, an estimated $52K sold.
Based on aggregated 13F filings for Q2 2022.